[Patient safety 4.0: "Failure of the Week" It's all about role modelling!].

Background: The rate of mistakes and near misses in clinical medicine remains staggering. The tendency to cover up mistakes is rampant in "name-blame-shame" cultures. The need for safe forums where mistakes can be openly discussed in the interest of patient safety is evident.

Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α.

Objective: Quality of life (QoL) is impaired in patients with hepatic encephalopathy and rifaximin-α can improve QoL within 6 months. This study assessed the importance of QoL as a therapeutic objective in hepatic encephalopathy management; whether QoL is routinely assessed in hepatic encephalopathy patients in clinical practice and the role of rifaximin-α in this context.

Methods: A survey was conducted of healthcare professionals (HCPs) from Europe and Australia involved in hepatic encephalopathy management.

Detection of SARS-CoV-2 from raw patient samples by coupled high temperature reverse transcription and amplification.

SARS-CoV-2 is spreading globally with unprecedented consequences for modern societies. The early detection of infected individuals is a pre-requisite to contain the virus. Currently, purification of RNA from patient samples followed by RT-PCR is the gold standard to assess the presence of this single-strand RNA virus.

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.

A consolidated overview of evidence for the effectiveness and safety/tolerability of hepatic encephalopathy (HE) treatment over the long term is currently lacking. We identified and assessed published evidence for the long-term (≥6 months) pharmacological management of HE with lactulose and/or rifaximin. A literature search was conducted in PubMed (cutoff date 05 March 2018) using the search terms 'hepatic encephalopathy+rifaximin' and 'hepatic encephalopathy+lactulose'.